Hepatitis C therapy with HCV NS5B polymerase inhibitors

By Soriano Vincent   Vispo Eugenia   de Mendoza Carmen   Labarga Pablo   Fernandez-Montero Jose Vicente   Poveda Eva   Treviño Ana   Barreiro Pablo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1161-1170

Informa Healthcare

Access to resources Recommend Favorite

QSAR and Molecular Modeling Studies on a Series of Indole-based Pyridone Analogues as HCV NS5B Polymerase Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 13, Iss. 8, 2016-10 ,pp. : 757-770

Bentham Science Publishers

Access to resources Recommend Favorite

Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure-Based Insight

By  

Current Bioactive Compounds, Vol. 4, Iss. 2, 2008-08 ,pp. : 86-109

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative QSAR Studies on the Novel Series of Thiazolones and Tetrazole Derivatives as HCV NS5B Polymerase Allosteric Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 286-297

Bentham Science Publishers

Access to resources Recommend Favorite

Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part II: Sulfonamides

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 6, 2005-09 ,pp. : 456-461

Bentham Science Publishers

Access to resources Recommend Favorite